Sign In
Buy PDSB
$1.08
-0.0800 (-6.90%)
At Close: Jun 03, 2026
PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pi
PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results
08:00am, Tuesday, 07'th Nov 2023
PRINCETON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of ta
PDS Biotech to Present at the LD Micro Main Event XVI
08:00am, Tuesday, 26'th Sep 2023
PRINCETON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of t
PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
04:05pm, Wednesday, 20'th Sep 2023
PRINCETON, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of t
PDS Biotech to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
04:05pm, Wednesday, 06'th Sep 2023
PRINCETON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of t
PDS Biotech's (PDSB) Shares Up 12% in a Month: Here's Why
12:46pm, Tuesday, 29'th Aug 2023
Shares of PDS Biotech (PDSB) show an upward trajectory as the company progresses toward initiating the late-stage development of its lead pipeline candidate.
PDS Biotechnology: Interim Data Reinforces Push Towards Phase 3 Study
12:22am, Monday, 14'th Aug 2023
PDS Biotechnology has achieved positive results in its phase 2 study of PDS0101 in combination with Merck's Keytruda for HPV16-positive head and neck cancer. The interim analysis showed 9 confirmed re
The Prognosis For PDS Biotechnology
05:30am, Sunday, 13'th Aug 2023
PDS Biotechnology Corporation has had a volatile stock performance in recent years. The company has made slow and steady progress advancing its pipeline and is well-liked within the analyst firm commu
PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2023 Financial Results
08:00am, Monday, 07'th Aug 2023
PRINCETON, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies
PDS Biotech to Present at BTIG Virtual Biotechnology Conference 2023
08:00am, Wednesday, 02'nd Aug 2023
PRINCETON, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies
PDS Biotechnology Post-ASCO Conference Call Tomorrow, June 6, at 8 a.m. ET
02:52pm, Monday, 05'th Jun 2023
FLORHAM PARK, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for
PDS Biotechnology: Promising Interim HNSCC Data Reaffirms Investment Prospects
03:40am, Saturday, 27'th May 2023
PDS Biotech's Phase 2 study shows potential breakthrough in treating HPV16-positive head and neck cancer. The study shows a 87.1% 12-month survival rate for ICI naive patients, nearly doubling typical
PDS Biotech (PDSB) Up 32% on Interim Data From HPV Cancer Study
09:35am, Friday, 26'th May 2023
PDS Biotech's (PDSB) shares gain as it announces encouraging interim data from the VERSATILE-002 study for treating HPV16-positive cancer patients.
PDS Biotech (PDSB) Completes Enrollment for HPV Cancer Study
01:01pm, Friday, 19'th May 2023
PDS Biotech (PDSB) shares gain as it completes patient enrollment in the second arm of the VERSATILE-002 study for treating HPV16-positive cancer patients.
PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2023 Financial Results
08:00am, Thursday, 04'th May 2023
FLORHAM PARK, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for
